About Alanyl-tRNA editing protein Aarsd1
Alanyl-tRNA editing protein Aarsd1 (AARSD1) is a protein
from Homo sapiens identified by UniProt accession
Q9BTE6, 412 residues long.
MolForge cross-references it against 0 known binders and
8 disease associations.
Target properties
| Protein name | Alanyl-tRNA editing protein Aarsd1 |
|---|
| UniProt accession | Q9BTE6 |
|---|
| Gene | AARSD1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 412 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (8)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.37
- body mass index · score 0.15
- total blood protein measurement · score 0.14
- creatinine measurement · score 0.07
- lymphocyte percentage of leukocytes · score 0.07
- monocyte percentage of leukocytes · score 0.03
- neutrophil percentage of leukocytes · score 0.02
- neoplasm · score 0.00
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q9BTE6-F1 | alphafold | PREDICTED | 93.61 | — |
Amino-acid sequence (412 residues)
MAFWCQRDSY AREFTTTVVS CCPAELQTEG SNGKKEVLSG FQVVLEDTVL FPEGGGQPDD RGTINDISVL RVTRRGEQAD HFTQTPLDPG SQVLVRVDWE RRFDHMQQHS GQHLITAVAD HLFKLKTTSW ELGRFRSAIE LDTPSMTAEQ VAAIEQSVNE KIRDRLPVNV RELSLDDPEV EQVSGRGLPD DHAGPIRVVN IEGVDSNMCC GTHVSNLSDL QVIKILGTEK GKKNRTNLIF LSGNRVLKWM ERSHGTEKAL TALLKCGAED HVEAVKKLQN STKILQKNNL NLLRDLAVHI AHSLRNSPDW GGVVILHRKE GDSEFMNIIA NEIGSEETLL FLTVGDEKGG GLFLLAGPPA SVETLGPRVA EVLEGKGAGK KGRFQGKATK MSRRMEAQAL LQDYISTQSA KE
Explore Alanyl-tRNA editing protein Aarsd1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets